Guidelines for safety management of granulocyte transfusion in Japan

详细信息    查看全文

• 作者：Akimichi Ohsaka (1)
  Atsushi Kikuta (2)
  Hitoshi Ohto (3)
  Akira Ohara (4)
  Akaru Ishida (5)
  Koji Osada (6)
  Tetsunori Tasaki (6)
  Akira Kamitamari (7)
  Asayuki Iwai (8)
  Shunro Kai (9)
  Taira Maekawa (10)
  Yasutaka Hoshi (6)
  
• 关键词：Granulocyte transfusion ; Guidelines ; Granulocyte colony ; stimulating factor ; Safety management
• 刊名：International Journal of Hematology
• 出版年：2010
• 出版时间：March 2010
• 年：2010
• 卷：91
• 期：2
• 页码：201-208
• 全文大小：182KB
• 参考文献：1. Dale D. Current management of chemotherapy-induced neutropenia: the role of colony-stimulating factors. Semin Oncol. 2003;30(4 Suppl 13):3-. CrossRef
  2. Bodey GP, Buckley M, Sathe YS, Freireich EJ. Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med. 1966;64:328-0.
  3. Hughes WT, Armstrong D, Bodey GP, Bow EJ, Brown AE, Calandra T, et al. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis. 2002;34:730-1. CrossRef
  4. Neuburger S, Maschmeyer G. Update on management of infections in cancer and stem cell transplant patients. Ann Hematol. 2006;85:345-6. CrossRef
  5. Christopher MJ, Link DC. Regulation of neutrophil homeostasis. Curr Opin Hematol. 2007;14:3-. CrossRef
  6. Ohsaka A, Kitagawa S, Sakamoto S, Miura Y, Takanashi N, Takaku F, et al. In vivo activation of human neutrophil functions by administration of recombinant human granulocyte colony-stimulating factor in patients with malignant lymphoma. Blood. 1989;74:2743-.
  7. Yuo A, Kitagawa S, Ohsaka A, Ohta M, Miyazono K, Okabe T, et al. Recombinant human granulocyte colony-stimulating factor as an activator of human granulocytes: potentiation of responses triggered by receptor-mediated agonists and stimulation of C3bi receptor expression and adherence. Blood. 1989;74:2144-.
  8. Anderlini P, Champlin RE. Biologic and molecular effects of granulocyte colony-stimulating factor in healthy individuals: recent findings and current challenges. Blood. 2008;111:1767-2. CrossRef
  9. Price TH. Granulocyte transfusion: current status. Semin Hematol. 2007;44:15-3. CrossRef
  10. Liles WC, Rodger E, Dale DC. Combined administration of G-CSF and dexamethasone for the mobilization of granulocytes in normal donors: optimization of dosing. Transfusion. 2000;40:642-. CrossRef
  11. Stroncek DF, Yau YY, Oblitas J, Leitman SF. Administration of G-CSF plus dexamethasone produces greater granulocyte concentrate yields while causing no more donor toxicity than G-CSF alone. Transfusion. 2001;41:1037-4. CrossRef
  12. Price TH, Bowden RA, Boeckh M, Bux J, Nelson K, Liles WC, et al. Phase I/II trial of neutrophil transfusions from donors stimulated with G-CSF and dexamethasone for treatment of patients with infections in hematopoietic stem cell transplantation. Blood. 2000;95:3302-.
  13. Atallah E, Schiffer CA. Granulocyte transfusion. Curr Opin Hematol. 2006;13:45-. CrossRef
  14. Anderlini P, K?rbling M, Dale D, Gratwohl A, Schmitz N, Stroncek D, et al. Allogeneic blood stem cell transplantation: considerations for donors. Blood. 1997;90:903-.
  15. Volk EE, Domen RE, Smith ML. An examination of ethical issues raised in the pretreatment of normal volunteer granulocyte donors with granulocyte colony-stimulating factor. Arch Pathol Lab Med. 1999;123:508-3.
  16. Bux J, Cassens U, Dielschneider T, Duchscherer M, Edel E, Eichler H, et al. Tolerance of granulocyte donors towards granulocyte colony-stimulating factor stimulation and of patients towards granulocyte transfusions: results of a multicentre study. Vox Sang. 2003;85:322-. CrossRef
  17. Kikuta A, Ohto H, Nemoto K, Mochizuki K, Sano H, Ito M, et al. Therapeutic transfusions of granulocytes collected by simple bag method for children with cancer and neutropenic infections: results of a single-centre pilot study. Vox Sang. 2006;91:70-. CrossRef
  18. Mochizuki K, Kikuta A, Ohto H, Nemoto K, Ito M, Sano H, et al. Extended storage of granulocyte concentrates mobilized by G-CSF with/without dexamethasone and collected by bag separation method. Transfus Med. 2007;17:296-03. CrossRef
  19. Adkins D, Ali S, Despotis G, Dynis M, Goodnough LT. Granulocyte collection efficiency and yield are enhanced by the use of a higher interface offset during apheresis of donors given granulocyte-colony-stimulating factor. Transfusion. 1998;38:557-4. CrossRef
  20. Rühl H, Bein G, Sachs UJ. Transfusion-associated graft-versus-host disease. Transfus Med Rev. 2009;23:62-1. CrossRef
  21. Brecher ME, editor. AABB technical manual, 15th ed. Bethesda: American Association of Blood Banks; 2005.
  22. Ohto H, Yasuda H, Noguchi M, Abe R. Risk of transfusion-associated graft-versus-host disease as a result of directed donations from relatives. Transfusion. 1992;32:691-. CrossRef
  23. Asai T, Inaba S, Ohto H, Osada K, Suzuki G, Takahashi K, et al. Guidelines for irradiation of blood and blood components to prevent post-transfusion graft-vs.-host disease in Japan. Transfus Med. 2000;10:315-0. CrossRef
  24. Nemoto K, Kikuta A, Ohto H, Sano H, Itoh M, Suzuki H. Collection by a simple bag method and the function of granulocytes in granulocyte transfusion. Int J Hematol. 2006;84:43-. CrossRef
  25. British Committee for Standards in Haematology. Transfusion guidelines for neonates and older children. Br J Haematol. 2004;124:433-3. CrossRef
  26. Liles WC, Klebanoff SJ. Regulation of apoptosis in neutrophils—Fas track to death? J Immunol. 1995;155:3289-1.
  27. Drewniak A, Boelens JJ, Vrielink H, Tool AT, Bruin MC, van den Heuvel-Eibrink M, et al. Granulocyte concentrates: prolonged functional capacity during storage in the presence of phenotypic changes. Haematologica. 2008;93:1058-7. CrossRef
  28. D’Souza A, Jaiyesimi I, Trainor L, Venuturumili P. Granulocyte colony-stimulating factor administration: adverse events. Transfus Med Rev. 2008;22:280-0. CrossRef
  29. Tigue CC, McKoy JM, Evens AM, Trifilio SM, Tallman MS, Bennett CL. Granulocyte-colony stimulating factor administration to healthy individuals and persons with chronic neutropenia or cancer: an overview of safety considerations from the Research on Adverse Drug Events and Reports project. Bone Marrow Transplant. 2007;40:185-2. CrossRef
  30. Pamphilon D, Nacheva E, Navarrete C, Madrigal A, Goldman J. The use of granulocyte-colony-stimulating factor in volunteer unrelated hemopoietic stem cell donors. Transfusion. 2008;48:1495-01. CrossRef
  31. Quillen K, Byrne P, Yau YY, Leitman SF. Ten-year follow-up of unrelated volunteer granulocyte donors who have received multiple cycles of granulocyte-colony-stimulating factor and dexamethasone. Transfusion. 2009;49:513-. CrossRef
  32. Sloand EM, Kim S, Maciejewski JP, Van Rhee F, Chaudhuri A, Barrett J, et al. Pharmacologic doses of granulocyte colony-stimulating factor affect cytokine production by lymphocytes in vitro and in vivo. Blood. 2000;95:2269-4.
  33. Ghodsi Z, Strauss RG. Cataracts in neutrophil donors stimulated with adrenal corticosteroids. Transfusion. 2001;41:1464-. CrossRef
  34. Burch JW, Mair DC, Meny GM, Moroff G, Ching SS, Naidoff MA, et al. The risk of posterior subcapsular cataracts in granulocyte donors. Transfusion. 2005;45:1701-. CrossRef
  35. Bishton M, Chopra R. The role of granulocyte transfusions in neutropenic patients. Br J Haematol. 2004;127:501-. CrossRef
  36. Schiffer CA, Aisner J, Daly PA, Schimpff SC, Wiernik PH. Alloimmunization following prophylactic granulocyte transfusion. Blood. 1979;54:766-4.
  37. Dutcher JP, Kendall J, Norris D, Schiffer C, Aisner J, Wiernik PH. Granulocyte transfusion therapy and amphotericin B: adverse reactions? Am J Hematol. 1989;31:102-. CrossRef
  
• 作者单位：Akimichi Ohsaka (1)
  Atsushi Kikuta (2)
  Hitoshi Ohto (3)
  Akira Ohara (4)
  Akaru Ishida (5)
  Koji Osada (6)
  Tetsunori Tasaki (6)
  Akira Kamitamari (7)
  Asayuki Iwai (8)
  Shunro Kai (9)
  Taira Maekawa (10)
  Yasutaka Hoshi (6)
  
  1. Department of Transfusion Medicine and Stem Cell Regulation, Juntendo University School of Medicine, 2-1-1 Hongo, Bunkyo-ku, Tokyo, 113-8421, Japan
  2. Department of Pediatrics, Fukushima Medical University, Fukushima, Japan
  3. Division of Blood Transfusion and Transplantation Immunology, Fukushima Medical University, Fukushima, Japan
  4. Division of Transfusion Medicine, Toho University Omori Medical Center, Tokyo, Japan
  5. Department of Internal Medicine, Tachikawa Hospital, Federation of National Public Service Personnel Mutual Aid Associations, Tokyo, Japan
  6. Blood Transfusion Service, Tokyo Jikei University Hospital, Tokyo, Japan
  7. Department of Pediatrics, Sasebo City General Hospital, Nagasaki, Japan
  8. Department of Pediatrics, Iwakuni Children’s Hospital, Kochi, Japan
  9. Department of Transfusion Medicine, Hyogo College of Medicine, Nishinomiya, Japan
  10. Department of Transfusion Medicine and Cell Therapy, Kyoto University Hospital, Kyoto, Japan
  

文摘

Granulocyte transfusion (GTX) has recently been revived by the ability to stimulate granulocyte donors with granulocyte colony-stimulating factor (G-CSF), resulting in a greatly increased number of cells that can be collected. However, there is a paucity of guidelines for assessing the appropriateness and safety management of GTX. The objective of this study was to establish guidelines for the safety management of GTX appropriate for the clinical situation in Japan. The Japan Society of Transfusion Medicine and Cell Therapy, Granulocyte Transfusion Task Force issued the first version of guidelines for GTX considering the safety management of both granulocyte donors and patients who receive GTX therapy. The current guidelines cover issues concerning: (1) the appropriateness of medical institutions, (2) management of granulocyte donors, (3) quality assurance of granulocyte concentrates, (4) administration of granulocyte concentrates, (5) evaluation of the effectiveness of GTX therapy, and (6) complications of GTX therapy. The simple ‘bag separation method-without apheresis may be recommended for granulocyte collection in pediatric patients. The first version of guidelines for GTX therapy has been established, which may be appropriate for the clinical situation in Japan. Care should be taken to perform the safety management of both granulocyte donors and patients who receive GTX therapy.